

- major, 2182t
 nail disorders, 380
 nausea and vomiting, 103e-2
 neurologic, 1793
 ovarian failure, 2132
 pulmonary, 621
 for Behçet's syndrome, 2194
 for breast cancer, 530
 for bullous pemphigoid, 372
 for Burkitt's lymphoma, 706
 for cerebellar degeneration, 618
 for CLL, 703
 for cold agglutinin disease, 659
 drug interactions of, 2130t
 for eosinophilic granulomatosis with polyangiitis, 1685, 2187
 for Ewing's sarcoma, 119e-4
 for gastric lymphoma, 536
 for gestational trophoblastic disease, 124e-5, 597
 for granulomatosis with polyangiitis, 2184-2185
 hepatotoxicity, 2025
 in HSCT preparation, 139e-2
 for inflammatory myopathies, 2201
 for interstitial lung diseases, 1711
 for lung cancer, 522
 for lupus nephritis, 1838
 for malignant pheochromocytoma, 2331
 for MS, 2672
 for mucous membrane pemphigoid, 374
 for myasthenia gravis, 2705
 for paraneoplastic encephalitis, 617
 for pemphigus vulgaris, 371
 for photoallergy, 390
 in pregnancy, 124e-4
 for SLE, 2130t, 2132
 for systemic sclerosis, 2163
 for testicular cancer, 591
 for thrombotic thrombocytopenic purpura, 730
 for vasculitis, 2182
- Cyclops*, 1412, 1422, 1435
 Cyclosarin, 262e-4. *See also* Nerve agents
 Cycloserine, 96e-4, 205e-6, 1116t
Cyclospora cayentanensis/cyclosporiasis
 clinical features of, 266, 1407
 diagnosis of, 245e-1, 245e-4t, 245e-6t, 1406t, 1407
 epidemiology of, 266, 1407
 treatment of, 1408
- Cyclosporine
 action of, 1828, 1829t, 1960, 2071
 adverse effects of, 348t, 667, 1829t, 1961, 2071
 carcinogenicity, 477t
 gingival hyperplasia, 237
 gout, 2218t
 hirsutism, 332, 380
 hyperkalemia, 310
 hyperperfusion syndrome, 463e-2f
 hypertension, 1617t, 2705
 myopathy, 2218t
 nephrotoxicity, 1828-1829, 1856t, 1862, 1864, 2071, 2705
 neurologic, 1793
 osteoporosis, 2492
 seizure, 2547t
 seizures, 1961
 skin cancer, 388
 thrombocytopenia, 729
 for angioedema, 2120
 for aplastic anemia, 666-667
 for atopic dermatitis, 354t
 for Behçet's syndrome, 2194
 contraindications to, 348
 drug interactions of, 34t
 azithromycin, 246e-4t
 azoles, 246e-3t
 calcium channel blockers, 42
 chloroquine, 246e-1t
 digoxin, 42t
 St. John's wort, 14e-4
 statins, 2199
- for epidermolysis bullosa acquisita, 374
 for IBD, 1960-1961
 for immunosuppression
 after kidney transplantation, 1828, 1829t
 after liver transplantation, 2071
 for inflammatory myopathies, 2201
 metabolism of, 34t, 42
 for myasthenia gravis, 2705
 for paroxysmal nocturnal hemoglobinuria, 662
 P-glycoprotein and, 34t
 for photoallergy, 390
 for psoriasis, 348, 348t, 354t
 for psoriatic arthritis, 2177
 for SJS/TEN, 383
 for SLE, 2133
 therapeutic monitoring of, 2764t
 for urticaria, 2120
- Cyclothymic disorder, 2717
 CYP1A1, 507
 CYP2C9
 in drug metabolism pathways, 34t
 drug responses and, 36, 39t, 41, 42
 warfarin dose requirements and, 754, 755, 755t
- CYP2C19
 in drug metabolism pathways, 34t
 drug responses and, 39t, 40, 277, 742-743, 747
- CYP2D6
 in autoimmune hepatitis, 372e-24t
 in drug metabolism pathways, 34t, 38f
 drug responses and, 34t, 39t, 40, 42
- CYP3A, 34t, 42, 277, 742
 CYP3A4, 40, 42, 935
 CYP3A5, 39t, 40
 CYP7A1 gene mutations, 2077
 CYP11A1, 2311
 CYP11A1 gene mutations, 2353, 2354t
 CYP11B1 gene mutations, 306, 434, 2356t
 CYP11B2 gene mutations, 306, 434, 2357
 CYP17 (17 α -hydroxylase) gene mutations, 372e-24t, 2311, 2353, 2354t
- CYP19 gene mutations, 2356t, 2357, 2366
 CYP21A1P pseudogene, 434
 CYP21A2 (21-hydroxylase gene) mutations
 in CAH, 2327, 2328t, 2355, 2356t
 gene conversion, 434
- CYP11A (cholesterol side-chain cleavage enzyme), 372e-24t
- Cyproheptadine
 for angioedema, 2119
 for carcinoid syndrome, 566
 for Cushing's syndrome, 2273
 for cyclic vomiting syndrome, 261
 for ergot alkaloid overdose/poisoning, 473e-8t
 for migraine prevention, 2593
 for serotonin syndrome, 473e-13t
 for urticaria, 2119
- Cyproterone acetate
 adverse effects of, 7e-6, 334
 for hirsutism, 334
 for hot flushes with androgen deprivation therapy, 7e-6
 for polycystic ovarian syndrome, 337
- CysLT (cysteinyl leukotrienes), 2114
 CysLT₁ receptor antagonist. *See* Montelukast; Zafirlukast
- Cyst, 340t. *See also specific types and sites*
 Cystathionine metabolism disorders, 434e-2t
 Cystathionine synthase, 642f, 643
 Cystathioninuria, 434e-2t
 Cystatin C, 291, 2759t
 Cystectomy, for bladder cancer, 576-577, 577t
 Cysteinyl-leukotrienes, 1678
 Cystic duct stump syndrome, 2082
- Cysticercosis
 chronic meningitis in, 908t
 clinical features of, 1430-1431
 diagnosis of, 245e-6t, 1431-1432, 1431t
 etiology of, 902
 neurologic. *See* Neurocysticercosis
 treatment of, 246e-1, 1432
- Cystic fibrosis (CF), 1697
 bronchiectasis in, 1695
 chest radiograph in, 308e-11f
 clinical features of
 clubbing, 2245
 gastrointestinal, 269, 1697
 hemoptysis, 245
 hepatic, 367e-2, 1697, 2062
 other organ systems, 1697
 pancreatic, 1697
 respiratory, 1697
 sinusitis, 226
 diagnosis of, 1698-1699
 disease spectrum of, 1699
 genetic considerations in
 CFTR gene mutations, 145e-5, 429f, 435, 480e-5, 1697-1698, 1698f
 heterozygote advantage, 442
 genetic testing for, 443, 450t
 incidence of, 1699
 infections in
Aspergillus, 1686
 nontuberculous mycobacterial, 776-777, 1128
P. aeruginosa, 145e-4f, 145e-5, 1044
 transmission of, 776-777
 newborn screening for, 1700
 pathogenesis of
 airflow resistance, 306e-3
 autoantigens, 372e-24t
 CFTR deficiency, 1697, 1698f, 1700v
 immunodeficiency, 375e-2
 pulmonary inflammation and remodeling, 1697
 treatment of
 CFTR defect correction, 1699
 early interventions for, 450t
 effectiveness of, 1700
 ivacaftor, 1699
 lung transplantation, 320e-1t, 320e-2
 personalized molecular therapies, 1699
 sequelae management, 1699
 typhoid fever resistance in, 145e-3
 vitamin E deficiency in, 96e-8
- Cystic fibrosis transmembrane conductance regulator. *See* CFTR protein
- Cystic medial necrosis, 1638
 Cystine metabolism disorders, 434e-2t
 Cystine stones, 1868, 1869f, 1871. *See also* Cystinuria; Nephrolithiasis
- Cystinosis, 434e-2t, 435e-1t
 Cystinuria
 clinical features of, 435e-1t, 435e-2, 1868, 1937
 genetic considerations in, 332e-7t, 332e-8, 435e-1t, 435e-2
 non-type I, 332e-7t
 treatment of, 435e-2
 type I, 332e-7t
- Cystitis. *See also* Urinary tract infections (UTIs)
 alkaline-encrusted, 981
 bacterial, 60e-1
 chemotherapy-induced, 103e-8
 clinical features of, 60e-1, 863
 definition of, 861
 diagnosis of, 865, 865f
E. coli, 60e-1, 1028
 epidemiology of, 861
 hematuria in, 294
 hemorrhagic, 139e-3, 1208, 1798
 interstitial. *See* Interstitial cystitis/bladder pain syndrome
 in men, 866
 prognosis of, 868
 recurrent, 868, 945t
 sexually transmitted, 870t
 treatment of, 60e-1, 866-867, 867t
- Cystoisospora belli*/cystoisosporiasis
 clinical features of, 266, 765t, 1407, 1957
 diagnosis of, 245e-4t, 245e-5t, 1406t, 1407
 epidemiology of, 245e-4t, 765t
 in HIV infection, 1257, 1407, 1957
 life-cycle hosts of, 245e-4t
 treatment of, 246e-9, 246e-12, 1407
- Cystopathy, diabetic, 2427